<DOC>
	<DOCNO>NCT00824538</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sunitinib work treat patient stage I , stage II , stage III breast cancer tumor cell bone marrow .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Stage I , Stage II , Stage III Breast Cancer Who Have Tumor Cells Bone Marrow</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine effect sunitinib malate occult tumor cell ( OTC ) bone marrow patient high-risk stage I-III breast cancer . Secondary - To evaluate number patient able tolerate drug 6 month complete study . - To evaluate toxicity drug patient . - To evaluate effect drug OTC peripheral blood . - To evaluate correlative marker , include endothelial cell , soluble cKIT , VEGF . - To evaluate relapse-free overall survival patient treated drug . OUTLINE : Patients receive oral sunitinib malate daily 6 month absence disease progression unacceptable toxicity . Patients undergo bone marrow aspiration peripheral blood sample collection baseline 6 12 month . Bone marrow aspirate sample analyze IHC flow cytometry . Peripheral blood sample analyze circulate tumor cell . After completion study treatment , patient follow 1 6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm highrisk breast cancer Stage IIII disease Has undergone definitive surgery without radiotherapy Completely resect disease Bone marrow aspirate positive occult tumor cell , define ≥ 10 occult tumor cells/mL IHC flow cytometry If patient receive either adjuvant therapy hormonal therapy alone , aspiration may perform diagnosis part large micrometastasis study UCSF , follow diagnosis patient underwent initial surgery elsewhere ( underwent surgery follow neoadjuvant therapy breast cancer ) If patient receive adjuvant chemotherapy , aspiration must perform ≥ 3 week completion chemotherapy Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 01 WBC count normal ( 3.410 x 10^9/L ) Hemoglobin &gt; 9.0 g/dL Platelet count normal ( 140450 x 10^9/L ) ANC normal ( 1.86.8 x 10^9/L ) Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN Alkaline phosphatase ≤ 1.5 time ULN AST ALT ≤ 2.5 time ULN TSH T4 level normal LVEF &gt; 50 % Systolic BP &lt; 140 mm Hg diastolic BP &lt; 90 mm Hg Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history HIV infection No concurrent severe illness would likely preclude study compliance No malignancy within past 5 year except basal cell carcinoma skin PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior sunitinib malate Prior adjuvant chemotherapy , include trastuzumab ( Herceptin® ) , allow provide complete within past 6 month Prior surgery follow neoadjuvant chemotherapy hormonal therapy allow No concurrent potent CYP3A4 inducers No concurrent trastuzumab Concurrent hormonal therapy radiotherapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>